NCT02413736 2025-03-12
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
Helsinki University Central Hospital
Phase 3 Active not recruiting
Clinical Trials
9 trialsNCT04138381 2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Unknown
NCT01275222 2021-06-25
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
Novartis
Phase 1/2 Completed
NCT01281865 2014-10-08
Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00031915 2013-06-19
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00084630 2013-02-28
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006357 2012-09-24
STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Completed
NCT00085475 2012-09-24
Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00116935 2011-12-30
Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)
Scandinavian Sarcoma Group
Phase 3 Completed